In addition, once prostate cancer progresses to become resistant to castration, the next line of therapy typically still involves targeting AR signaling through the use of AR signaling inhibitors (ARSI) such as enzalutamide, which inhibits androgen binding to the AR, AR nuclear translocation, and its binding to cis-regulatory elements [119,120]. Here, AR is linked to prostate carcinoma.